Phase 2b Results of Viamet’s Oral VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis Presented at IDSOG Annual Meeting

– Presentation detailed the Company’s REVIVE study data demonstrating
unprecedented results in the treatment of RVVC –

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–#IDSOGViamet
Pharmaceuticals, Inc.
today announced the presentation of results
from REVIVE, a Phase 2b clinical trial of VT-1161 in the treatment of
patients with recurrent vulvovaginal candidiasis (RVVC), at the
Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual
Meeting in Park City, Utah. VT-1161 is a highly potent and selective,
orally-administered inhibitor of fungal CYP51 that has demonstrated
broad-spectrum activity against yeast, dermatophyte, endemic and
multi-drug resistant fungal pathogens. The REVIVE study, presented by
Jack Sobel, M.D., during an oral presentation on Thursday, August 10,
demonstrated unprecedented efficacy and safety in patients with RVVC, a
condition associated with a very high burden of disease and for which
there are no approved therapies.

“Recurrent yeast infections are a pervasive problem, affecting
approximately 5% to 8% of women. While the physical symptoms of
infection are distressing, the emotional and psychological consequences
of RVVC have a significant impact on the quality of life for those
affected,” stated Robert Schotzinger, M.D., Ph.D., CEO of Viamet.
“VT-1161 is highly potent against a broad spectrum of Candida
species, the primary fungal pathogens responsible for RVVC, and has
clinically demonstrated a durable response against re-infection. We
believe that VT-1161 has the potential to be a best-in-class treatment
option for patients suffering from RVVC and the first FDA approved
treatment for this very common disease.”

“The current treatment approach for patients with RVVC is typically
treatment of the acute infection each time one occurs. In some cases,
this is followed by long term suppressive therapy with oral fluconazole,
a drug with a limited antifungal spectrum and which has been associated
with safety liabilities, drug-drug-interactions and potential pregnancy
effects,” said Dr. Sobel, Wayne State University School of Medicine, one
of the clinical investigators in the REVIVE study. “VT-1161 demonstrated
a high degree of efficacy and very impressive safety during the 48-week
REVIVE study. The low re-infection rates observed in the VT-1161 treated
patients were very impressive compared to other therapies previously
studied in RVVC.”

The presentation titled, “Results from a Phase 2, Randomized,
Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the
Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients
with Recurrent Vulvovaginal Candidiasis,” was delivered by Dr. Sobel. In
the intent-to-treat population, defined as all randomized subjects, the
proportion of subjects with one or more vulvovaginal candidiasis
episodes through 48 weeks ranged from 0-7% in the VT-1161 arms compared
to 52% in the placebo arm (p<0.0001 for all active arms compared to placebo). In the per protocol analysis, which included patients evaluable through 48 weeks, the recurrence rate of one or more vulvovaginal candidiasis episodes in the placebo arm was 66% while the four VT-1161 arms ranged from 0-11% (p<0.0001 for all active arms compared to placebo). Throughout the study, VT-1161 was very well tolerated and there was a lower incidence of adverse events reported in all VT-1161 arms compared to placebo. VT-1161 also showed no evidence of adverse effects on laboratory parameters, which have been an issue for other oral treatment approaches for RVVC. In addition, VT-1161 displayed potent activity against a range of Candida species including C.
glabrata
, which is becoming more pronounced and which has shown
resistance to other antifungal agents such as fluconazole.

About the Phase 2b REVIVE study
REVIVE (REcurrent Vulvovaginal
Candidiasis Inhibition: an Oral VT-1161 Tablet Evaluation)
was a randomized, double-blind, placebo-controlled, 48-week clinical
trial of VT-1161 in patients with RVVC. The trial evaluated two dose
levels of VT-1161 (150 mg and 300 mg) administered once weekly for
either 11 or 23 weeks, following an initial one-week daily loading dose
period. The trial enrolled 215 patients at 32 sites throughout the U.S.
At baseline, the mean number of vulvovaginal candidiasis episodes per
patient in the prior 12 months ranged from 4.6 to 5.2 across the study
arms. Patients were eligible to enroll in the trial if they had a
documented history of RVVC, presented to the physician with a
vulvovaginal candidiasis infection, and had completed treatment of the
active infection with fluconazole, an antifungal agent approved in the
U.S. for the treatment of vulvovaginal candidiasis. The primary efficacy
endpoint was the proportion of subjects with one or more
culture-verified vulvovaginal candidiasis episodes through 48 weeks.

About VT-1161
VT-1161 is a potent and selective,
orally-administered inhibitor of fungal CYP51 which recently
successfully completed Phase 2b clinical trials for the treatment of onychomycosis,
or fungal nail infection, and recurrent vulvovaginal candidiasis (RVVC),
a common and difficult to treat infection in women. VT-1161 blocks the
production of ergosterol, an essential component of the fungal cell
membrane. In preclinical studies, VT-1161 has demonstrated
broad-spectrum activity against both dermatophytes and Candida
species, including those species that cause onychomycosis and RVVC.
Given the clinical and preclinical profile of VT-1161, Viamet believes
that it may avoid the side effects that limit the use of current oral
antifungal therapies, such as liver toxicity and drug-drug interactions.
The U.S. Food and Drug Administration (FDA) has granted Qualified
Infectious Disease Product (QIDP) and Fast Track designations to VT-1161
for the treatment of RVVC
.

About RVVC
Recurrent vulvovaginal candidiasis (RVVC) is
defined as the occurrence of three or more episodes of vulvovaginal
candidiasis within a 12-month period. RVVC is estimated to occur in 5%
to 8% of women in the United States during their child-bearing years.
The infection involves the vaginal mucosa and surrounding tissues and
can be a source of significant discomfort. RVVC is ranked by patients
above migraine and similar to asthma and chronic obstructive pulmonary
disease with regard to its negative impact on quality of life and also
results in a significant loss of work time. There are currently no
approved therapies in the U.S. for the treatment of RVVC.

About Viamet (www.viamet.com)
Viamet
discovers and develops breakthrough therapies based on our leadership in
metalloenzyme chemistry and biology. Our clinical portfolio includes
novel agents to treat both chronic and life threatening fungal
infections. We also leverage our metalloenzyme expertise in other
therapeutic areas including oncology and orphan diseases. Focusing on
the needs of patients and clinicians, we design our drug candidates to
achieve superior efficacy and safety profiles compared to currently
marketed drugs.

This press release includes forward-looking statements. Actual
results may vary materially from these statements. There are many
important risks affecting Viamet’s business, including that clinical
trials may not be commenced, or if commenced, may not be successful,
regulatory approvals may not be obtained and approved products, if any,
may not achieve commercial success. The Viamet group of companies
includes Viamet Pharmaceuticals Holdings, LLC and its operating
subsidiaries, Viamet Pharmaceuticals, Inc., VPS-2, Inc., VPS-3, Inc. and
Viamet Pharmaceuticals (Bermuda), Ltd. The Viamet group of companies are
based in the Research Triangle Park region of North Carolina, USA and
Hamilton, Bermuda.

Contacts

MacDougal Biomedical Communications
Stefanie Tuck, +1 781-235-3060
stuck@macbiocom.com